Literature DB >> 21467745

Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats.

Hisakazu Sanada1, Masashi Sekimoto, Ayaka Kamoshita, Masakuni Degawa.   

Abstract

An animal model of rheumatoid arthritis can be elicited in male Lewis rats by a single intradermal injection of liquid paraffin containing dead Mycrobacterium tuberculosis (MT adjuvant) into the planar surface of the right hind-foot. In the present study, we used this animal model to examine the changes in expression of hepatic cytochorme P450 (CYP) enzymes during the development of the arthritis. Swellings of the MT adjuvant-injected hind-foot initially occurred at 1-8 days after the injection. Thereafter, the swelling gradually become more severe up to 13 days later and was maintained for up to 25 days. Swellings of the other hind-foot was also observed after 12 days and gradually become more severe up to 15 days with maintenance of the severe swelling for up to 25 days. The gene expression levels and enzyme activities of hepatic CYP 3A and CYP2B subfamily enzymes at 1, 12, and 25 days after the MT adjuvant injection were significantly decreased, compared with the corresponding time-matched controls. The decreases in the gene expression levels and activities of all the enzymes examined were closely correlated with increases in the expression levels of the inflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin (IL)-1α, interleukin-1β and interleukin-6, which were produced in the liver. All of the present findings demonstrate that hepatic CYP3A and CYP2B subfamily enzymes are decreased during the development of MT adjuvant-induced arthritis and further suggest that the decreases are dependent on the production of inflammatory cytokines in the liver.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467745     DOI: 10.2131/jts.36.181

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  7 in total

1.  Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.

Authors:  Xiling Jiang; Yanli Zhuang; Zhenhua Xu; Weirong Wang; Honghui Zhou
Journal:  AAPS J       Date:  2016-03-09       Impact factor: 4.009

2.  Effect of N-Feruloylserotonin and Methotrexate on Severity of Experimental Arthritis and on Messenger RNA Expression of Key Proinflammatory Markers in Liver.

Authors:  Ľudmila Pašková; Viera Kuncírová; Silvester Poništ; Danica Mihálová; Radomír Nosáľ; Juraj Harmatha; Iveta Hrádková; Tomáš Čavojský; František Bilka; Katarína Šišková; Ingrid Paulíková; Lýdia Bezáková; Katarína Bauerová
Journal:  J Immunol Res       Date:  2016-07-31       Impact factor: 4.818

Review 3.  Abnormal Glucose Metabolism in Rheumatoid Arthritis.

Authors:  Hui Pi; Haotong Zhou; Huan Jin; Yaogui Ning; Youlian Wang
Journal:  Biomed Res Int       Date:  2017-04-26       Impact factor: 3.411

4.  A Comparative Pharmacokinetic Study by UHPLC-MS/MS of Main Active Compounds after Oral Administration of Zushima-Gancao Extract in Normal and Adjuvant-Induced Arthritis Rats.

Authors:  Jinjun Shan; Wenjuan Qian; Linxiu Peng; Lianghui Chen; An Kang; Tong Xie; Liuqing Di
Journal:  Molecules       Date:  2018-01-22       Impact factor: 4.411

Review 5.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

Review 6.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

7.  Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases.

Authors:  Lujing Wang; Yang Chen; Wangda Zhou; Xin Miao; Honghui Zhou
Journal:  Clin Transl Sci       Date:  2021-10-20       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.